Michael A Bookman
Overview
Explore the profile of Michael A Bookman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
98
Citations
4454
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sehouli J, Boer J, Brand A, Oza A, ODonnell J, Bennett K, et al.
Int J Gynecol Cancer
. 2024 Nov;
34(11):1677-1684.
PMID: 39496422
Findings from clinical trials have led to advancement of care for patients with gynecologic malignancies. However, restrictive inclusion of patients into trials has been widely criticized for inadequate representation of...
2.
Lee J, Brady M, Miller A, Moore R, MacKay H, McNally L, et al.
J Clin Oncol
. 2024 Oct;
42(36):4305-4316.
PMID: 39361946
Purpose: We assessed the efficacy of cediranib, olaparib, and cediranib/olaparib compared with standard-of-care chemotherapy (SOC) in platinum-resistant or platinum-refractory epithelial ovarian cancer (PROC). Patients And Methods: NRG-GY005 is an open-label,...
3.
Brown J, Miller A, Holman L, Backes F, Nagel C, Bender D, et al.
Gynecol Oncol
. 2024 Sep;
190:283-290.
PMID: 39265466
Objectives: To assess the efficacy and toxicity of paclitaxel and carboplatin (PC) compared to bleomycin, etoposide, and cisplatin (BEP) for treatment of newly diagnosed Stage IIA-IV or recurrent chemotherapy-naive ovarian...
4.
Creutzberg C, Kim J, Eminowicz G, Allanson E, Eberst L, Kim S, et al.
Lancet Oncol
. 2024 Aug;
25(9):e420-e431.
PMID: 39214113
The Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Consensus Conference on Clinical Research (ECCC) was held in Incheon, South Korea, Nov 2-3, 2023. The aims were to develop consensus statements for...
5.
Landen C, Buckanovich R, Sill M, Mannel R, Walker J, DiSilvestro P, et al.
J Clin Oncol
. 2024 May;
42(21):2537-2545.
PMID: 38776484
Purpose: The interleukin-6/Janus kinase (JAK)/signal transducers and activators of transcription 3 axis is a reported driver of chemotherapy resistance. We hypothesized that adding the JAK1/2 inhibitor ruxolitinib to standard chemotherapy...
6.
Sia T, Tew W, Purdy C, Chi D, Menzin A, Lovecchio J, et al.
Gynecol Oncol
. 2023 May;
173:130-137.
PMID: 37148580
Objective: To assess the effect of age on overall survival (OS) in women with ovarian cancer receiving chemotherapy. Secondary objectives were to describe the effect of age on treatment compliance,...
7.
You B, Purdy C, Copeland L, Swisher E, Bookman M, Fleming G, et al.
J Clin Oncol
. 2022 Oct;
40(34):3965-3974.
PMID: 36252167
Purpose: In patients with high-grade ovarian cancer, predictors of bevacizumab efficacy in first-line setting are needed. In the ICON-7 trial, a poor tumor intrinsic chemosensitivity (defined by unfavorable modeled cancer...
8.
Vergote I, Gonzalez-Martin A, Lorusso D, Gourley C, Mirza M, Kurtz J, et al.
Lancet Oncol
. 2022 Jul;
23(8):e374-e384.
PMID: 35901833
The Gynecologic Cancer InterGroup (GCIG) sixth Ovarian Cancer Conference on Clinical Research was held virtually in October, 2021, following published consensus guidelines. The goal of the consensus meeting was to...
9.
You B, Sehgal V, Hosmane B, Huang X, Ansell P, Dinh M, et al.
J Clin Oncol
. 2022 Jul;
41(1):107-116.
PMID: 35867965
Purpose: In VELIA trial, veliparib combined with carboplatin-paclitaxel, followed by maintenance (veliparib-throughout) was associated with improved progression-free survival (PFS) compared with carboplatin-paclitaxel alone in patients with high-grade ovarian carcinomas. We...
10.
Liu J, Brady M, Matulonis U, Miller A, Kohn E, Swisher E, et al.
J Clin Oncol
. 2022 Mar;
40(19):2138-2147.
PMID: 35290101
Purpose: Platinum-based chemotherapy is the standard of care for platinum-sensitive ovarian cancer, but complications from repeated platinum therapy occur. We assessed the activity of two all-oral nonplatinum alternatives, olaparib or...